We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test
Read MoreHide Full Article
Key Takeaways
QDEL launches the QUICKVUE Influenza SARS Test, expanding its respiratory solutions portfolio.
QuidelOrtho's test detects flu A, flu B and SARS-CoV-2 antigens from one sample with 10-minute results.
The launch supports QDEL's Molecular Diagnostics and Point of Care units across U.S. clinical settings.
Last week, QuidelOrtho Corporation (QDEL - Free Report) announced the availability of QUICKVUE Influenza + SARS Test. The CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay is the latest addition to the company’s QUICKVUE portfolio and has been designed for professional use in physician office laboratories, urgent care centers, emergency departments, pharmacies and decentralized hospital labs.
The latest launch of the QUICKVUE Influenza + SARS Test expands QuidelOrtho's portfolio of respiratory solutions and is currently available in the United States through its existing distribution channels. However, the test is not intended for in-home use.
The latest addition and subsequent expansion of QuidelOrtho's portfolio are expected to significantly boost its Molecular Diagnostics and Point of Care business units and strengthen its foothold in the niche space across the nation.
Significance of QDEL’s Product Launch
Per QuidelOrtho, the QUICKVUE Influenza + SARS Test is expected to deliver rapid, simultaneous detection and differentiation of influenza A, influenza B and SARS-CoV-2 antigens from a single patient sample and provide results within 10 minutes. Management believes that this capability will likely aid clinicians in distinguishing between COVID-19 and seasonal flu infections, which present similar symptoms, enabling timely treatment decisions and improved patient outcomes.
Industry Prospects in Favor of QuidelOrtho
Per a report by Grand View Research, the global point-of-care diagnostics market was estimated at $47.8 billion in 2024 and is anticipated to reach $68.5 billion by 2030 at a CAGR of 5.8%. Factors like the ability of point-of-care diagnostic tests to provide immediate results and technological advancements are likely to drive the market.
Given the market potential, the latest launch is expected to provide a significant boost to QuidelOrtho’s business.
QDEL’s Notable Development
In August, QuidelOrtho reported its second-quarter 2025 results, wherein its Molecular Diagnostics revenues recorded robust growth on both a reported basis and at constant exchange rate (CER).
Comparison With Peers
A notable peer of QuidelOrtho is Qiagen N.V. (QGEN - Free Report) . This month, Qiagen received CE-IVDR certification for its full portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis Panel. The QIAstat-Dx system now offers CE-IVDR certified panels for respiratory, gastrointestinal and central nervous system infections that help clinicians diagnose infectious diseases with greater speed and accuracy. The same month, Qiagen announced the launch of QIAstat Dx Rise – a version of the QIAstat-Dx automated syndromic testing system.
Another notable player in the Molecular Diagnostics space and peer of QuidelOrtho is Hologic, Inc. (HOLX - Free Report) . In July, Hologic announced its third-quarter fiscal 2025 results, wherein it recorded a robust uptick in Diagnostics revenues both on a reported basis and at CER. This was primarily driven by Hologic’s higher molecular diagnostics sales, whose revenues were also solid on a reported basis and at CER on the back of higher sales of its BV CV/TV and Panther Fusion assays. Excluding COVID-19 revenues, Hologic’s molecular diagnostics revenues were also robust both on a reported basis and at CER.
QuidelOrtho’s peer and another notable name in the Diagnostics space is Thermo Fisher Scientific Inc. (TMO - Free Report) . In July, Thermo Fisher reported its second-quarter 2025 results, wherein its Specialty Diagnostics revenues witnessed strength. The same month, Thermo Fisher debuted two new solutions, LabLink360 and Thermo Scientific MAS Max quality controls, designed to support quality control assurance and streamline workflows in clinical laboratories, at the Association for Diagnostics & Laboratory Medicine Conference.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test
Key Takeaways
Last week, QuidelOrtho Corporation (QDEL - Free Report) announced the availability of QUICKVUE Influenza + SARS Test. The CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay is the latest addition to the company’s QUICKVUE portfolio and has been designed for professional use in physician office laboratories, urgent care centers, emergency departments, pharmacies and decentralized hospital labs.
The latest launch of the QUICKVUE Influenza + SARS Test expands QuidelOrtho's portfolio of respiratory solutions and is currently available in the United States through its existing distribution channels. However, the test is not intended for in-home use.
The latest addition and subsequent expansion of QuidelOrtho's portfolio are expected to significantly boost its Molecular Diagnostics and Point of Care business units and strengthen its foothold in the niche space across the nation.
Significance of QDEL’s Product Launch
Per QuidelOrtho, the QUICKVUE Influenza + SARS Test is expected to deliver rapid, simultaneous detection and differentiation of influenza A, influenza B and SARS-CoV-2 antigens from a single patient sample and provide results within 10 minutes. Management believes that this capability will likely aid clinicians in distinguishing between COVID-19 and seasonal flu infections, which present similar symptoms, enabling timely treatment decisions and improved patient outcomes.
Industry Prospects in Favor of QuidelOrtho
Per a report by Grand View Research, the global point-of-care diagnostics market was estimated at $47.8 billion in 2024 and is anticipated to reach $68.5 billion by 2030 at a CAGR of 5.8%. Factors like the ability of point-of-care diagnostic tests to provide immediate results and technological advancements are likely to drive the market.
Given the market potential, the latest launch is expected to provide a significant boost to QuidelOrtho’s business.
QDEL’s Notable Development
In August, QuidelOrtho reported its second-quarter 2025 results, wherein its Molecular Diagnostics revenues recorded robust growth on both a reported basis and at constant exchange rate (CER).
Comparison With Peers
A notable peer of QuidelOrtho is Qiagen N.V. (QGEN - Free Report) . This month, Qiagen received CE-IVDR certification for its full portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis Panel. The QIAstat-Dx system now offers CE-IVDR certified panels for respiratory, gastrointestinal and central nervous system infections that help clinicians diagnose infectious diseases with greater speed and accuracy. The same month, Qiagen announced the launch of QIAstat Dx Rise – a version of the QIAstat-Dx automated syndromic testing system.
Another notable player in the Molecular Diagnostics space and peer of QuidelOrtho is Hologic, Inc. (HOLX - Free Report) . In July, Hologic announced its third-quarter fiscal 2025 results, wherein it recorded a robust uptick in Diagnostics revenues both on a reported basis and at CER. This was primarily driven by Hologic’s higher molecular diagnostics sales, whose revenues were also solid on a reported basis and at CER on the back of higher sales of its BV CV/TV and Panther Fusion assays. Excluding COVID-19 revenues, Hologic’s molecular diagnostics revenues were also robust both on a reported basis and at CER.
QuidelOrtho’s peer and another notable name in the Diagnostics space is Thermo Fisher Scientific Inc. (TMO - Free Report) . In July, Thermo Fisher reported its second-quarter 2025 results, wherein its Specialty Diagnostics revenues witnessed strength. The same month, Thermo Fisher debuted two new solutions, LabLink360 and Thermo Scientific MAS Max quality controls, designed to support quality control assurance and streamline workflows in clinical laboratories, at the Association for Diagnostics & Laboratory Medicine Conference.